Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

238.95 -1.91 (-0.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 606,463
Open 241.01
Bid (Size) 225.50 (1)
Ask (Size) 248.00 (1)
Prev. Close 240.86
Today's Range 235.43 - 242.93
52wk Range 158.38 - 242.93
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Buy These 3 Low-Beta Stocks To Sail Through A Choppy Market
Creating a portfolio of low-beta stocks is of utmost importance since the securities will deliver healthy returns and provide a shield against volatile market conditions. 
Via Talk Markets
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year. 
Via Investor's Business Daily

Performance

YTD
+13.45%
+13.45%
1 Month
+6.30%
+6.30%
3 Month
+36.36%
+36.36%
6 Month
+11.30%
+11.30%
1 Year
+32.75%
+32.75%

More News

Read More
Will Investors Notice Exciting Sign On United Therapeutics's Chart?
Via Benzinga
United Therapeutics Provides an Update on Its Organ Printing Programs
From United Therapeutics Corporation
Via Business Wire
Expert Ratings for United Therapeutics
Via Benzinga
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Short Volatility Alert: United Therapeutics Corporation
Via Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
Via Investor's Business Daily
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Via Benzinga
United Therapeutics Announces FDA Approval of Tyvaso DPI™
From United Therapeutics Corporation
Via Business Wire
United Therapeutics's Return on Invested Capital Insights
Via Benzinga
7 Biotech Stocks With Key Catalysts for May
Via InvestorPlace
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Recap: United Therapeutics Q1 Earnings
Via Benzinga
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
Earnings Scheduled For May 4, 2022
Via Benzinga
Earnings Outlook For United Therapeutics
Via Benzinga
United Therapeutics Q1 2022 Earnings Conference Call On May 4, 2022 At 09:00 AM ET
Via Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
From United Therapeutics Corporation
Via Business Wire
First Human With Pig Heart Transplant Dies: Reuters
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
Via Newswire.com
United Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.